BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19930156)

  • 1. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
    Miyazawa M; Ohsawa R; Tsunoda T; Hirono S; Kawai M; Tani M; Nakamura Y; Yamaue H
    Cancer Sci; 2010 Feb; 101(2):433-9. PubMed ID: 19930156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
    Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
    Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
    Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.
    Suzuki N; Hazama S; Ueno T; Matsui H; Shindo Y; Iida M; Yoshimura K; Yoshino S; Takeda K; Oka M
    J Immunother; 2014 Jan; 37(1):36-42. PubMed ID: 24316554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The development of a novel cancer vaccine using Peptide vaccine for patients with advanced pancreatic cancer].
    Miyazawa M; Yamaue H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1903-5. PubMed ID: 22202233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
    Nishida S; Koido S; Takeda Y; Homma S; Komita H; Takahara A; Morita S; Ito T; Morimoto S; Hara K; Tsuboi A; Oka Y; Yanagisawa S; Toyama Y; Ikegami M; Kitagawa T; Eguchi H; Wada H; Nagano H; Nakata J; Nakae Y; Hosen N; Oji Y; Tanaka T; Kawase I; Kumanogoh A; Sakamoto J; Doki Y; Mori M; Ohkusa T; Tajiri H; Sugiyama H
    J Immunother; 2014; 37(2):105-14. PubMed ID: 24509173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.
    Matsuyama M; Ishii H; Furuse J; Ohkawa S; Maguchi H; Mizuno N; Yamaguchi T; Ioka T; Ajiki T; Ikeda M; Hakamada K; Yamamoto M; Yamaue H; Eguchi K; Ichikawa W; Miyazaki M; Ohashi Y; Sasaki Y
    Invest New Drugs; 2015 Apr; 33(2):490-5. PubMed ID: 25502982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
    Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
    J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
    Kim DH; Shiozawa S; Usui T; Yoshimatsu K; Otani T; Tsunoda T; Nakamura Y; Ogawa K
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2271-3. PubMed ID: 19106593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
    Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
    Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer.
    Asahara S; Takeda K; Yamao K; Maguchi H; Yamaue H
    J Transl Med; 2013 Nov; 11():291. PubMed ID: 24237633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
    Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
    Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
    Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
    Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
    Yamaue H; Tsunoda T; Tani M; Miyazawa M; Yamao K; Mizuno N; Okusaka T; Ueno H; Boku N; Fukutomi A; Ishii H; Ohkawa S; Furukawa M; Maguchi H; Ikeda M; Togashi Y; Nishio K; Ohashi Y
    Cancer Sci; 2015 Jul; 106(7):883-90. PubMed ID: 25867139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
    Yanagimoto H; Mine T; Yamamoto K; Satoi S; Terakawa N; Takahashi K; Nakahara K; Honma S; Tanaka M; Mizoguchi J; Yamada A; Oka M; Kamiyama Y; Itoh K; Takai S
    Cancer Sci; 2007 Apr; 98(4):605-11. PubMed ID: 17309598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
    Yutani S; Komatsu N; Yoshitomi M; Matsueda S; Yonemoto K; Mine T; Noguchi M; Ishihara Y; Yamada A; Itoh K; Sasada T
    Oncol Rep; 2013 Sep; 30(3):1094-100. PubMed ID: 23784011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
    Iinuma H; Fukushima R; Inaba T; Tamura J; Inoue T; Ogawa E; Horikawa M; Ikeda Y; Matsutani N; Takeda K; Yoshida K; Tsunoda T; Ikeda T; Nakamura Y; Okinaga K
    J Transl Med; 2014 Apr; 12():84. PubMed ID: 24708624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
    J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
    Niethammer AG; Lubenau H; Mikus G; Knebel P; Hohmann N; Leowardi C; Beckhove P; Akhisaroglu M; Ge Y; Springer M; Grenacher L; Buchler MW; Koch M; Weitz J; Haefeli WE; Schmitz-Winnenthal FH
    BMC Cancer; 2012 Aug; 12():361. PubMed ID: 22906006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.